key: cord-0938802-pexbhg6p
authors: Pilaquinga, Fernanda; Morey, Jeroni; Torres, Marbel; Seqqat, Rachid; Piña, María de las Nieves
title: Silver nanoparticles as a potential treatment against SARS‐CoV‐2: A review
date: 2021-02-27
journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol
DOI: 10.1002/wnan.1707
sha: 2e1ad4d63765b0437e260d6786937b9dbb2e9876
doc_id: 938802
cord_uid: pexbhg6p

Several human coronaviruses (HCoVs) are distinguished by the ability to generate epidemics or pandemics, with their corresponding diseases characterized by severe respiratory illness, such as that which occurs in severe acute respiratory syndrome (SARS‐CoV), Middle East respiratory syndrome (MERS‐CoV), and, today, in SARS‐CoV‐2, an outbreak that has struck explosively and uncontrollably beginning in December 2019 and has claimed the lives of more than 1.9 M people worldwide as of January 2021. The development of vaccines has taken one year, which is why it is necessary to investigate whether some already‐existing alternatives that have been successfully developed in recent years can mitigate the pandemic's advance. Silver nanoparticles (AgNPs) have proved effective in antiviral action. Thus, in this review, several in vitro and in vivo studies of the effect of AgNPs on viruses that cause respiratory diseases are analyzed and discussed to promote an understanding of the possible interaction of AgNPs with SARS‐CoV‐2. The study focuses on several in vivo toxicological studies of AgNPs and a dose extrapolation to humans to determine the chief avenue of exposure. It can be concluded that the use of AgNPs as a possible treatment for SARS‐CoV‐2 could be viable, based on comparing the virus' behavior to that of similar viruses in in vivo studies, and that the suggested route of administration in terms of least degree of adverse effects is inhalation. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology. Therapeutic Approaches and Drug Discovery > Nanomedicine for Respiratory Disease. Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials.

electrochemical biosensors, ssDNA-capped AuNPs were placed on graphene-coated filter paper . Further, used with porous nanomaterials, such as metal-organic frameworks (MOF), which is a class of porous polymers consisting of clusters and metal ions coordinated with polytopic organic linkers, NPs can detect different viruses, including SARS-CoV-2 (Rabiee et al., 2020; Seo et al., 2020) . Another biosensor using cobaltdoped titanium dioxide nanotubes showed excellent results in detecting SARS-CoV-2 virus within 30 s in a wide range of concentrations (Vadlamani, Uppal, Verma, & Misra, 2020) .

Although NPs' antiviral properties have been determined, the reaction of the human body and, therefore, the efficacy of NPs as drugs depends on the distribution of plasma proteins on their surface. NPs are designed to direct their action toward binding and penetration and in that way block the replication of viruses. They use mechanisms that either directly or indirectly inactivate the virus, which prevents the virus from binding to the host cells and blocks viral replication, as seen in Figure 1 . Other mechanisms of action of NPs are related to their local action against receptors on the surface of the virus, where they alter the membrane potential and block virus penetration to a great extent (Abdul et al., 2020; Gurunathan et al., 2020) .

Among the different types of metallic NPs, the antiviral activity of silver NPs (AgNPs) on SARS-CoV-2 is of particular interest (Argentiere, Cella, Cesaria, Milani, & Lenardi, 2016; Das et al., 2020; Durán, Silveira, Durán, & Martinez, 2015; Hossain, 2020; Teirumnieks, Balchev, Ghalot, & Lazov, 2021) . AgNPs are known for their high antimicrobial activity, biocompatibility, and low toxicity in eukaryotic cells. There are few in vitro studies regarding the use of AgNPs against SARS-CoV-2 (Jeremiah, Miyakawa, Morita, Yamaoka, & Ryo, 2020) , as in vivo studies are a more urgent need.

This study presents a review of the use of AgNPs against SARS-CoV-2. The properties of AgNPs and their possible interaction, in vitro and in vivo studies on viruses causing respiratory diseases, the toxicity of AgNPs induced by inhalation, dermal, and oral routes for AgNPs, and the dose extrapolation to humans, as a possible treatment for this virus.

F I G U R E 1 Possible mechanisms of the use of nanotechnology through nanobubbles, nanofibers, nanotraps, nanorobots, nanopolymers, nanodiamonds, and nanotransporters of biomolecules and drugs with antiviral action 2 | CORONAVIRUS SARS-CoV-2

The Coronaviridae family of viruses has affected mankind since the beginning of the twentieth century, and these virus' sudden mutations in short periods have complicated the development of a specific treatment to limit their spread and lethality (Bonilla-Aldana et al., 2020; de Wit, van Doremalen, Falzarano, & Munster, 2016; Lin, Hsu, & Lin, 2014) . For example, SARS-CoV crossed the species barrier in late 2002: the bat that carries the virus transferred it to an intermediate species, which then transferred it to humans, and its transmission was nosocomial and presented a lethality of 30% (Aguanno et al., 2018; Lin et al., 2018) . Another HCoV disease, MERS-CoV, was reported in the 1980s in camels; however, it did not begin to spread in humans until 2012, with a mortality of 36% (Chan et al., 2013) . Two other HCoVs, HCoV-NL63 and HCoV-HKU1, appeared in 2004 and 2005, respectively;  only minimal control efforts were needed, so their lethality is not fully known (Kasmi, Khataby, Souiri, & Ennaji, 2020) .

SARS-CoV-2 was first detected in December 2019 in Wuhan City, Hubei Province (China); it has a percentage of lethality of 2% to 3% but is extremely contagious (Scavone et al., 2020; Weiss & Navas-Martin, 2005) . The virus produces symptoms similar to those of a common cold and more serious diseases such as severe pneumonia and respiratory failure. It particularly affects elderly people with preexisting conditions . The main route of infection is through the respiratory tract, although various sources of infection, such as tears and feces, have been reported . The virus can survive as a particle suspended in the air for 3 h, and its incubation period is from 2 to 14 days (Dong, Du, & Gardner, 2020) .

SARS-CoV-2 is the seventh type of coronavirus isolated in humans; it belongs to the genus β CoV, is round in shape with a crown appearance, and measures 60 to 140 nm in diameter under an electron microscope . It has a positive-sense, single-stranded genome made of RNA (+ssRNA), contains 29,891 nucleotides encoding 9880 amino acids (−29.8 kbp), and has a 5 0 cap structure and 3 0 poly-A tail. The genomic RNA between ORF1a and ORF1b (open reading frames) is used for the direct production of two polypeptides: polyprotein 1a/1ab (pp1a/pp1ab), which encodes nonstructural proteins (nsps) (Guo et al., 2020) .

The physiological binding of SARS-CoV-2 in the body is via epithelial cells containing surface sialic acids that bind with galactose α-2,6. Sialic acid is an abundant molecule in all cells and defines the particular tropism of respiratory viruses, the epithelial cells that line the human trachea contain mainly carbohydrates and have an α-2,6 bond (Allen, Tennant, & Franklin, 2019; Diefenbach, Gnafakis, & Shomrat, 2020; Kumazaki, Shimomura, Kiyono, Ochiya, & Yamamoto, 2020) , which is why SARS-CoV-2 generally first enters the body here.

SARS-CoV-2 binds to its receptor in the host cell through the transmembrane spike protein (S), which forms homodimers that leave the viral surface. It is composed of two units, S1 and S2, which are responsible for binding with the host cell receptor and viral membrane fusion. The virus has been shown to bind to the angiotensinconverting enzyme 2 (ACE2) receptor and is a significant determinant for the pathogenesis of CD209L infection (a C-type lectin, also called L-SIGN, and dipeptidyl peptidase 4 [DPP4], also known as CD26), which promotes transmission to humans and other species and their cellular infection (Li, Geng, Peng, Meng, & Lu, 2020) . The envelope protein (E) is located in an intracellular traffic site, such as the Golgi complex, where it participates in its selfassembly and is considered very important in the production and maturation of the viral particle (Schoeman & Fielding, 2019) . The nucleocapsid protein (N) directs the genome to replicate, transcribe, and package. Additionally, the membrane protein (M) collaborates in the fixation of the nucleocapsid to the membrane of internal structures such as the Golgi complex and is responsible for the transmembrane transport of nutrients, the release of the virion, and the formation of the envelope (Cui, Li, & Shi, 2019) . Once the viral genome is inside the cytoplasm and translates into two polyproteins and structural proteins, it begins to replicate . The envelope (E) glycoproteins are inserted into the Golgi endoplasmic reticulum membrane, and the nucleocapsid is formed by the combination of genomic RNA and the N protein. In these vesicles containing the virus particles, viral replication and transcription occur (Kasmi et al., 2020) .

One of the most commonly used inorganic materials for fighting bacterial and viral diseases is silver (Sondi & Salopek-Sondi, 2004) . Silver is a noble metal that has been used since antiquity. In ionic form, it is used in concentrations higher than 40% to treat skin diseases such as warts and granulomas. As 1% silver sulfadiazine, it is used for burns and skin ulcers (Murthy, 2007; Ramírez, 2013) . Currently, the use of ionic colloidal silver as an alternative treatment for SARS-CoV-2 has gained popularity through the Internet. However, the Food and Drug Administration (FDA) does not recognize it as a safe and effective agent (Morrill et al., 2013) .

Like NPs, AgNPs have a wide range of biomedical applications (Prabhu & Poulose, 2012) because of their antibacterial capacity and selective toxicity against microorganisms (Wong & Liu, 2010) . Various studies have indicated that AgNPs can adhere to the cellular membrane, altering cellular permeability, and the cell's respiratory functions. It is possible they not only interact with the membrane surface but also penetrate the bacteria. Further, silver ions can link with thiol groups of biomolecules and with phosphorus sulfide compounds, such as when DNA inactivates bacteria. Many studies concerning AgNPs' antimicrobial activity have been published Devanesan, Ponmurugan, AlSalhi, & Al-Dhabi, 2020; Elmehbad & Mohamed, 2020; Garibo et al., 2020; Rao, Saptami, Venkatesan, & Rekha, 2020; Sharma et al., 2020; Taghavizadeh Yazdi et al., 2020) .

AgNPs have a highly reactive surface area in addition to unique optical and catalytic properties, unlike ionic colloidal silver (Marimuthu et al., 2020) . Their surface chemistry controls AgNPs' properties and functionality. Various studies have demonstrated that silver nanoconjugates can easily enter living cells (Abdellah, Sliem, Bakr, & Amin, 2018) . The use of organic compounds to stabilize AgNPs, whose function is to coat the surface and avoid coalescence phenomena that induce aggregation and, consequently, loss of characteristic properties. Stabilizing agents can be simple molecules or polymers, with or without surfactant characteristics, that interact with the surface of the AgNPs through their hydrophobic segments Randazzo, Fabra, Falcó, López-Rubio, & Sánchez, 2018) .

The size and shape of AgNPs play a very important role in antiviral activity. Several studies have shown that dimensions smaller than 10 nm produce much more reactive surfaces (Marimuthu et al., 2020) . The shape can also vary-for example, triangular, bar, or spiral-which drastically affects the mechanism of viral action; those of the spherical and cylindrical type are more phagocytosed (Soiza, Donaldson, & Myint, 2018) .

Many studies have pointed out the antiviral activity that AgNPs exert on different virus types that cause respiratory illness, such as influenza (Mehrbod et al., 2009) , HPIV3 (Galdiero et al., 2013) , human adenovirus serotype 3 (Ad3) (Nana Chen, Zheng, Yin, , respiratory syncytial virus (RSV) (Yang, Li, & Huang, 2016) , and Rift Valley fever (RFV) (Borrego et al., 2016) . In a recent in vitro study using polyvinylpyrrolidone-coated AgNPs in Vero cells infected with SARS-CoV-2, the almost complete inhibition of the virus' replication was confirmed using NPs with diameters of 10 nm, as well as lower toxicity compared to NPs of smaller and larger sizes (Jeremiah et al., 2020) . Other viruses for which AgNPs have been assayed, include the human immunodeficiency virus (HIV) (Elechiguerra et al., 2005 (Lu et al., 2008) , Ebola virus (Yen et al., 2015) , Tacaribe virus (Speshock, Murdock, Braydich-Stolle, Schrand, & Hussain, 2010) , monkeypox virus (Rogers, Parkinson, Choi, Speshock, & Hussain, 2008) , African swine fever virus (Thi Ngoc Dung et al., 2020) , porcine epidemic diarrhea virus (PEDV) , polio virus (Huy et al., 2017) , and dengue virus (Suresh et al., 2015) , among others.

Both in vitro and in vivo studies have been conducted with AgNPs and various viruses. When comparing studies on AgNPs' antiviral activity with that of other metallic NPs (e.g., iron oxides NPs, ZnONPs, AuNPs, TiO 2 NPs, CaONPs, and ZrONPs) for a specific virus like influenza A, we find a higher number of both in vitro and in vivo studies (Wieczorek, Szutkowska, & Kierzek, 2020) . The first study related to the antiviral properties of AgNPs was conducted by Mehrbod et al. (2009) , which demonstrated the 78% reduction of viral load after exposing the influenza virus to the treatment.

Finally, AgNPs have been tested in an influenza vaccine as an adjuvant to improve the immune response by increasing the production of immunoglobulin IgA, a predominant antibody in seromucosal secretions and an important defense against viral infections (Sanchez-Guzman et al., 2019) . Table 1 summarizes the most important information of in vitro and in vivo studies of AgNPs antiviral activity on different viruses that cause respiratory diseases, such as SARS-CoV-2, influenza, HPIV3, Ad3, RSV, and RFV.

According to the studies carried out, AgNPs act directly with the viral genome through the proteins found on its surface (Mehrbod et al., 2009; Xiang et al., 2011) . Infection with influenza viruses H1N1 and H7N3, HPIV3, Ad3, RSV, RVF, and SARS-CoV-2 starts by binding protein S to the specific host receptor (Borrego et al., 2016; Chen et al., 2013; Fatima et al., 2016; Galdiero et al., 2013; Huang et al., 2020; Park et al., 2018; Yang et al., 2016) . This protein allows the virus to bind with the ACE2 receptor conversion enzyme (Jiang & He, 2012) . According to its crystal structure, SARS-CoV-2 contains disulfide bonds Cys336-Cys361, Cys379-Cys432, and Cys391-Cys525. Cys480-Cys488 is key in the junction between the virus crest and the N-terminal helix of ACE2 (Kang et al., 2020; Walls et al., 2020) . As Figure 2 shows, AgNPs bind to membrane of spike (S) glycoprotein through disulfide bonds, due to their chemical affinity for sulfur (Chung, Chen, & Chen, 2008; Yuan, He, Huang, & Su, 2019) . This interaction hinders the internalization of the virus in the cells by inhibiting the interaction between the glycoprotein and its specific receptor. Cellular absorption of AgNPs occurs through the processes of endocytosis and macropinocytosis. Once inside the cell, the AgNPs inhibit the virus's replication capacity (Galdiero et al., 2011) .

AgNPs also appear to exert an effect on H (hemagglutinin) and N (neuraminidase) proteins, which are the main determinants of pathogenicity. If AgNPs are also combined with oseltamivir (OTV), FlulPed, zanamivir, and amantadine (Alghrair et al., 2019; Li, Lin, Zhao, Guo, et al., 2016; drugs, which possess antiviral properties and are currently used against SARS-CoV-2, reactive oxygen species (ROS) are produced, which minimize the destruction of MDFK cells and inhibit the neuraminidase and hemagglutinin activity of viruses with healthy cells . Coatings also modify AgNPs' effects; for example, chitosan stabilizes AgNPs and allows them to increase their virucidal capacity, though their size modifies the mechanism of action (Mori et al., 2013) . The use of other types of coatings, such as chitosan (Mori et al., 2013) , SiO 2 (Park et al., 2018) , Cinnamomun cassia (Fatima et al., 2016) , Curcuma longa (Yang et al., 2016) , and polyvinylpyrrolidone (Borrego et al., 2016; Morris et al., 2019) , markedly reduce cellular cytotoxicity compared to uncoated AgNPs. The antioxidant, anti-inflammatory, and antibacterial properties from the plant from which the coating is derived.

Despite the marked antiviral effect of AgNPs, currently in Europe, there is no specific legislation for NPs, although they are classified as a "substance" in the European Regulation of Chemical Substances (REACH) (Regulation No. 1907 of the Parliament, December 18, 2006 . In the United States, the regulation of AgNPs by the FDA is limited by the impact that silver, as an element, can have on the environment (Sood & Chopra, 2018) The use of AgNPs is in the preclinical phase, and a general assessment of public health risk is not yet possible, although several products are on the market. Due to their applications, especially in relation to pandemic control, we must assume that human exposure to AgNPs will increase substantially in the immediate future. The main factors that determine the toxic effects of AgNPs in organisms are classified according to the route of exposure (entry, F I G U R E 2 Mechanism of AgNPs' antiviral effect on different stages of virus replication: (1) interaction with viral surface, (2) interference with viral attachment, (3) inhibition of virus penetration into the cell, (4) interaction with viral genome, (5) inhibition of genome replication, (6) inhibition of protein synthesis concentration, and duration), factors that depend on the exposed organism, and those related to AgNPs' intrinsic toxicity (del Rocío Coutiño, Avila, & Helguera, 2017) , bioavailability, and accumulation in the body. There are three main routes of exposure to AgNPs: inhalation, dermal/parenteral, and oral. Table 2 shows various published in vivo studies on toxicity that have used AgNPs. According to these studies, AgNPs' cytotoxic effect depends on their size, tissue distribution, penetration capacity, and cellular absorption (Khandelwal et al., 2014) .

After entering the body, the largest AgNPs can be exhaled, while the smallest AgNPs can be deposited in the lungs and can reach other organs through the bloodstream. With average sizes of 15 to 30 nm and in concentrations of 0.5 to 381 μg/m 3 , according to histopathological analysis, no significant changes regarding AgNPs presence after exposure were found in the nasal cavities (Hyun et al., 2008) , lungs (Song et al., 2013) , or liver (Kim et al., 2011) , among other organs (Ji et al., 2007) . However, at high concentrations above 2.9 mg/m 3 , AgNPs can produce brain injuries after being inhaled (Kwon et al., 2012) . Further, the existence of an electric charge on NPs' surface can affect their adhesiveness in biological tissues (Sharma, Mukkur, Benson, & Chen, 2009 ). Negatively charged NPs allow for efficient DNA encapsulation, although their stability is very low. In contrast, positively charged NPs form complexes with DNA plasmids through electrostatic interactions, promoting their encapsulation and increasing their stability. Furthermore, it has been shown that AgNPs improve immunogenicity when they are administered through the mucosa. However, they also have the ability to form electrostatic interactions with blood proteins, ions, and others (Kumar et al., 2002) .

In parenteral injections, AgNPs cytotoxicity increases with a size of 20 to 100 nm and concentrations of 0.1 to 1000 mg/kg, causing lung (Wang et al., 2014) , liver (Tiwari, Jin, & Behari, 2011) , renal (Tang et al., 2009) , and cerebral lesions (Rahman et al., 2009) .

The level of toxicity from oral ingestion is intermediate. AgNPs ranging from 3 to 60 nm were used (Gaillet & Rouanet, 2015) , but NPs size were not as decisive as dose for oral toxicity. The dosage range was from 0.5 μg to 500 mg/L. Doses of 10 mg/kg caused weight loss (Shahare & Yashpal, 2013) , doses higher than 300 mg/kg led to liver disorders (Kim et al., 2008) , and doses higher than 1000 mg/kg generated oxidative stress (Adeyemi & Faniyan, 2014) . In terms of the spread of ionic colloidal silver and AgNPs, less distribution was observed with AgNPs in organs such as the liver, spleen, and kidneys, among others (Loeschner et al., 2011; Park, 2013) . However, accumulation is minimal compared to the subcutaneous or parenteral injection route; this is because many of the applied doses are largely expelled in feces (Gaillet & Rouanet, 2015) .

Regarding dosage of AgNPs, few studies have involved human participants, so extrapolation of in vivo toxicological information from rats to humans is of great importance. Certain dosimetric concepts can be considered, adapted to the parameters for each species because of their organic structural differences (Kim et al., 2011) . Extrapolation to estimate human exposure through AgNPs inhalation has already been performed (Oller & Oberdörster, 2010) . Specifically, rats have an alveolar surface area of 0.409 m 2 , while that of humans is 62.7 m 2 . Correlation is done through multipath particle dosimetry modeling, using exposure concentration in relation to the deposited mass per alveolar surface area. Using this model, through aerosol tests and measuring the elimination of AgNPs 90 days after exposure, it was determined that rats exposed to 100 μg/m 3 is equivalent to 19 μg/m 3 in humans (Ji & Yu, 2012) .

Nevertheless, it is difficult to determine AgNPs toxicity for humans because studies on exposure in humans are still scarce (del Rocío Coutiño et al., 2017) . A study carried out on workers exposed to AgNPs showed that exposure time is not the most important factor for the generation of toxicity; in certain cases, the exposure exceeded five years with concentrations of 0.35 and 1.35 mg/m 3 , and in none of these cases were there hematological or blood changes (Lee, Mun, Park, & Yu, 2012) . Further, exposure levels depend on the activity. A person who recovers silver in close proximity to soluble compounds has concentrations of 1.3 to 20 mg/L, while jewelry manufacturers present concentrations of 0.2 to 2.8 mg/L, showing that concentrations for the manufacturers of AgNPs are much lower than the limit. Therefore, long exposure time does not affect workers' health (Armitage, White, & Wilson, 1996) . With medium-level exposure, blood levels of AgNPs should range between 0.1 and 23 mg/L, while for sporadic exposure, levels should be around ≤0.1 mg/L (Armitage et al., 1996; Lee et al., 2012) . However, studies of NPs conditions should be expanded, especially those focusing on levels in the lungs, as highest exposure is by inhalation.

AgNPs' inhibitory effects on SARS-CoV-2 may be a new clinical strategy for the prevention of infection during its early dissemination stage. This review analyzed the in vitro and in vivo effects of AgNPs on some viruses that produce respiratory diseases. To initiate animal studies, according to the in vivo toxicological analysis, the routes of exposure to AgNPs (2014) AgNPs-tannic acid-PVP 8-20 100, 1000, 5000 mg/kg (7,14, and 21 days), oral Mice Wistar Kidney, liver, testicles, and brain AgNPs increased the concentration of malondialdehyde and superoxide dismutase, although they also decreased glutathione, Stransferase, and catalase levels; this indicates that AgNPs may be agents of oxidative stress Adeyemi and Faniyan (2014) AgNPs-sodium hydroxide-hydrazine 3-20 5, 10, 15, 20 mg/kg (21 days), oral Mice Swiss-albino Kidney, liver, spleen, brain, and lung The animals presented a significant reduction in their weight; maximum weight losses were observed at doses higher than 10 mg/kg Shahare and Yashpal (2013) by inhalation present fewer adverse effects, unlike oral and parenteral administration. With an average AgNPs size of 10 nm and in concentrations of 0.5 to 381 μg/m 3 , there were no significant changes in the nasal cavities when AgNPs were inhaled. If extrapolated from rats to humans, 100 μg/m 3 of AgNPs is equivalent to 19 μg/m 3 , respectively. Available studies on the toxicity of AgNPs are scarce and sometimes contradictory. Further, evidence for coating AgNPs to reduce their toxicity and enhance their specificity is still emerging. Therefore, it is necessary to carry out a greater number of studies on the effective dose and possible toxic effects of the use of AgNPs to establish safe conditions for humans against highly virulent viruses such as SARS-CoV-2.

Thanks to Miguel Vivas-Rodríguez for assisting in the bibliographic information search. 

Pt-, Rh-, Ru-, and Cu-single-wall carbon nanotubes are exceptional candidates for design of anti-viral surfaces: A theoretical study

Green synthesis and biological activity of silver-curcumin nanoconjugates

Role of nanotechnology in diagnosing and treating COVID-19 during the Pandemi

Antioxidant status of rats administered silver nanoparticles orally

MERS: Progress on the global response, remaining challenges and the way forward

Rapid, ultrasensitive, and quantitative detection of SARS-CoV-2 using antisense oligonucleotides directed electrochemical biosensor chip

Nano-enabled sensing approaches for pathogenic bacterial detection

Enhanced inhibition of influenza virus infection by peptide-noble-metal nanoparticle conjugates

Effect of inclusion or exclusion of epithelial cells in equine respiratory cytology analysis

Awareness about nanotechnology and its applications in drug industry among pharmacy students

Research and patents on coronavirus and COVID-19: A review

Silver nanoparticles in complex biological media: Assessment of colloidal stability and protein corona formation

The determination of silver in whole blood and its application to biological monitoring of occupationally exposed groups. The Annals of Occupational Hygiene

Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethane sulfonate

Coronavirus infections reported by ProMED

Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo

How can nanotechnology help to combat COVID-19? Opportunities and urgent need

Is nanotechnology helping in the fight against COVID-19?

Interspecies transmission and emergence of novel viruses: Lessons from bats and birds

Inhibitory effects of silver nanoparticles against adenovirus type 3 in vitro

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study

Materials science approaches in the development of broad-spectrum antiviral therapies

The surface modification of silver nanoparticles by phosphoryl disulfides for improved biocompatibility and intracellular uptake

Targeting viral entry for treatment of hepatitis B and C virus infections

Origin and evolution of pathogenic coronaviruses

Silver-based nanomaterials as therapeutic agents against coronaviruses: A review

SARS and MERS: Recent insights into emerging coronaviruses

Nanopartículas de plata: Mecanismos de entrada, toxicidad y estrés oxidativo

Cytotoxic and antimicrobial efficacy of silver nanoparticles synthesized using a traditional phytoproduct, asafoetida gum

Innate lymphoid cell-epithelial cell modules sustain intestinal homeostasis

An interactive web-based dashboard to track COVID-19 in real time

Enhanced oligonucleotide-nanoparticle conjugate stability using thioctic acid modified oligonucleotides

Glutathione-capped Ag 2 s nanoclusters inhibit coronavirus proliferation through blockage of viral RNA synthesis and budding

Antiviral activity of graphene oxide-silver nanocomposites by preventing viral entry and activation of the antiviral innate immune response

Silver nanoparticle protein corona and toxicity: A mini-review

Interaction of silver nanoparticles with HIV-1

Designing, preparation and evaluation of the antimicrobial activity of biomaterials based on chitosan modified with silver nanoparticles

In vitro antiviral activity of Cinnamomum cassia and its nanoparticles against H7N3 influenza A virus

CLIA (clinical laboratory improvement amendments) testing. Coronavirus Disease

Silver nanoparticles: Their potential toxic effects after oral exposure and underlying mechanisms -A review

Silver nanoparticles as potential antiviral agents

Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 3

Green synthesis of silver nanoparticles using Lysiloma acapulcensis exhibit high-antimicrobial activity

Silver nanoparticles for delivery purposes

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -An update on the status

Antiviral potential of nanoparticles-Can nanoparticles fight against coronaviruses?

Globalization of infectious diseases: the impact of migration

A study on understanding potential gold and silver nanoparticle: An overview

Inhibition effect of silver nanoparticles on herpes simplex virus 2

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

Cytotoxicity and antiviral activity of electrochemical -Synthesized silver nanoparticles against poliovirus

Effects of repeated silver nanoparticles exposure on the histological structure and mucins of nasal respiratory mucosa in rats

Nanomedicine for COVID-19: Potential of copper nanoparticles

Potent antiviral effect of silver nanoparticles on SARS-CoV-2. Biochemical and Biophysical Research Communications

Twenty-eight-day inhalation toxicity study of silver nanoparticles in Sprague-Dawley rats

Estimation of human equivalent exposure from rat inhalation toxicity study of silver nanoparticles using multipath particle dosimetry model

Anticuerpos monoclonales neutralizantes contra el coronavirus asociado al síndrome respiratorio agudo severo (Patent No. 2 384 497)

Nanotechnology based approaches for combatting COVID-19 viral infection

No small matter: A perspective on nanotechnology-enabled solutions to fight COVID-19

A pilot study of the antiviral activity of anionic and cationic polyamidoamine dendrimers against the Middle East respiratory syndrome coronavirus

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites

Implementation of nanotechnology in fuel cells

Coronaviridae: 100,000 years of emergence and reemergence

Inactivation of human coronavirus by titania nanoparticle coatings and UVC radiation: Throwing light on SARS-CoV-2

Application of silver nanoparticles in viral inhibition: A new hope for antivirals

In vivo genotoxicity of silver nanoparticles after 90-day silver nanoparticle inhalation exposure. Safety and Health at Work

Twenty-eight-day oral toxicity, genotoxicity, and gender-related tissue distribution of silver nanoparticles in Sprague-Dawley rats

Intranasal Gene Transfer by Chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection

Are graphene and graphene-derived products capable of preventing COVID-19 infection? Medical Hypotheses

Cell-type specific tumorigenesis with Ras oncogenes in human lung epithelial cells

Acute pulmonary toxicity and body distribution of inhaled metallic silver nanoparticles

Mode of antiviral action of silver nanoparticles against HIV-1

A health surveillance case study on workers who manufacture silver nanomaterials

Adaptations of nanoscale viruses and other protein cages for medical applications

Nanomedicine formulations for the delivery of antiviral drugs: A promising solution for the treatment of viral infections

Transmission of COVID-19 in the terminal stages of the incubation period: A familial cluster

Molecular immune pathogenesis and diagnosis of COVID-19

Reversal of H1N1 influenza virus-induced apoptosis by silver nanoparticles functionalized with amantadine

Silver nanoparticle based codelivery of oseltamivir to inhibit the activity of the H1N1 influenza virus through ROS-mediated signaling pathways

Biomedical applications of plasmon resonant metal nanoparticles

Antiviral natural products and herbal medicines

Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes

The inhibition of H1N1 influenza virus-induced apoptosis by silver nanoparticles functionalized with zanamivir

Distribution of silver in rats following 28 days of repeated oral exposure to silver nanoparticles or silver acetate

Silver nanoparticles inhibit hepatitis B virus replication

Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding

The splenocyte proliferative response and cytokine secretion in mice after 28-day oral administration of silver nanocolloid

Silver nanoparticles in dye effluent treatment: A review on synthesis, treatment methods, mechanisms, photocatalytic degradation, toxic effects and mitigation of toxicity

Nanoparticle-based strategies to combat COVID-19

Vitro antiviral effect of "nanosilver" on influenza virus

Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles

The challenge of emerging and re-emerging infectious diseases

Antiviral activity of silver nanoparticle/chitosan composites against H1N1 influenza A virus

Spectrum of antimicrobial activity associated with ionic colloidal silver

Antiviral and immunomodulatory activity of silver nanoparticles in experimental RSV infection

Nanoparticles in modern medicine: State of the art and future challenges

Incorporation of particle size differences between animal studies and human workplace aerosols for deriving exposure limit values

Tannic acid modified silver nanoparticles show antiviral activity in herpes simplex virus type 2 infection

Face masks and nanotechnology: Keep the blue side up

Toxicokinetic differences and toxicities of silver nanoparticles and silver ions in rats after single oral administration

Inactivation of influenza A virus via exposure to silver nanoparticle-decorated silica hybrid composites

Ebola virus disease (the killer virus): Another threat to humans and bioterrorism: Brief review and recent updates

Astodrimer sodium, dendrimer antiviral, inhibits replication of SARS-CoV-2 in vitro

Rapid SARS-CoV-2 detection by carbon nanotube-based near-infrared nanosensors

Silver nanoparticles: Mechanism of antimicrobial

Point-of-use rapid detection of SARS-CoV-2: Nanotechnology-enabled solutions for the COVID-19 pandemic

Expression of genes related to oxidative stress in the mouse brain after exposure to silver-25 nanoparticles

Nanotechnology in cosmetics: Opportunities and challenges

Los virus y la nanomedicina

Polymers and biopolymers with antiviral activity: Potential applications for improving food safety

Microwave-assisted rapid synthesis of silver nanoparticles using fucoidan: Characterization with assessment of biocompatibility and antimicrobial activity

A preliminary assessment of silver nanoparticle inhibition of monkeypox virus plaque formation

Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgAmediated mucosal immunity

Ayurvedic metal nanoparticles could be novel antiviral agents against SARS-CoV-2. International Nano Letters

Current pharmacological treatments for COVID-19: What's next?

Coronavirus envelope protein: Current knowledge

Carbon nanomaterials to combat virus: A perspective in view of COVID-19

Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor

Toxic effects of repeated oral exposure of silver nanoparticles on small intestine mucosa of mice

Multiplexed nanomaterial-based sensor array for detection of COVID-19 in exhaled breath

Unveiling antimicrobial and anticancerous behavior of AuNPs and AgNPs moderated by rhizome extracts of Curcuma longa from diverse altitudes of Himalaya

Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems

Nanomedicine: Principles, properties, and regulatory issues

Vaccine against arteriosclerosis: An update. Therapeutic Advances in Vaccines

Silver nanoparticles as antimicrobial agent: A case study on E. coli as a model for Gram-negative bacteria

Recovery from silver-nanoparticle-exposure-induced lung inflammation and lung function changes in Sprague Dawley rats

Regulatory approval of silver nanoparticles

Interaction of silver nanoparticles with Tacaribe virus

Potential of graphene-based materials to combat COVID-19: Properties, perspectives, and prospects

Tackling the growing threat of dengue: Phyllanthus niruri-mediated synthesis of silver nanoparticles and their mosquitocidal properties against the dengue vector Aedes aegypti (Diptera: Culicidae)

Anticancer, antimicrobial, and dye degradation activity of biosynthesised silver nanoparticle using Artemisia kopetdaghensis

Pulmonary and systemic distribution of inhaled ultrafine silver particles in rats

Nanotechnology-based disinfectants and sensors for SARS-CoV-2

Distribution, translocation and accumulation of silver nanoparticles in rats

Antibacterial and anti-viral effects of silver nanoparticles medicine against COVID-19 -A review

Silver nanoparticles as potential antiviral agents against African swine fever virus

Dose-dependent in-vivo toxicity assessment of silver nanoparticle in Wistar rats

Functionalized TiO 2 nanotube-based electrochemical biosensor for rapid detection of SARS-CoV-2

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Use of coated silver nanoparticles to understand the relationship of particle dissolution and bioavailability to cell and lung toxicological potential

Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus

Coronavirus disease (COVID-19) situation reports: Weekly epidemiological update and weekly operational update

Anti-influenza strategies based on nanoparticle applications

Silver nanoparticles-The real "silver bullet" in clinical medicine?

Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro

Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo

Inhibition of SARS-CoV-2 replication by acidizing and RNA lyase-modified carbon nanotubes combined with photodynamic thermal effect

Curcumin modified silver nanoparticles for highly efficient inhibition of respiratory syncytial virus infection

Multicolored silver nanoparticles for multiplexed disease diagnostics: Distinguishing dengue, yellow fever, and Ebola viruses

Characterization of interfacial behaviour of ortho-positioned diaryl disulfide on silver substrates by surface-enhanced Raman scattering and electroreduction

Diagnosing dengue virus infection: Rapid tests and the role of micro/nanotechnologies

Cellular nanosponges inhibit SARS-CoV-2 infectivity

A simple magnetic nanoparticles-based viral RNA extraction method for efficient detection of SARS-CoV-2

Silver nanoparticles as a potential treatment against SARS-CoV-2: A review